Regenxbio Shares Plunge Over 30% After FDA Holds RGX-111 and RGX-121
The FDA placed clinical holds on Regenxbio's RGX-111 and RGX-121 gene therapy trials after identifying a tumor in a participant, triggering a 30-35% share price decline. Levi & Korsinsky has launched an investigation into whether Regenxbio omitted material safety concerns from its Q3 2025 earnings call disclosures.
1. Trading Surge on Volume Spike
Regenxbio shares jumped 5.4% in the most recent session on a trading volume of 3.83 million shares, nearly six times the three-month daily average of 684,271. The surge followed a flurry of analyst estimate revisions: while three firms raised full-year sales forecasts by an average of 8%, two downgraded earnings per share projections by 12% over the next two quarters. This mix of upward revenue tweaks and downward profit revisions suggests near-term volatility as investors weigh stronger top-line expectations against potential margin pressures from ongoing R&D investments.
2. FDA Clinical Holds Raise Safety Concerns
On January 28, 2026, Regenxbio disclosed via Form 8-K that the FDA placed clinical holds on its RGX-111 and RGX-121 gene therapy programs after identifying a tumor in a trial participant. Following this announcement, the stock initially dropped 30–35% in premarket trading. These holds affect two of the company’s four mid- to late-stage pipeline assets and may delay potential Biologics License Application submissions by an estimated 9–12 months, according to regulatory consultancy BioTrack Advisors.
3. Shareholder Investigation Targets Disclosure Practices
On January 29, 2026, law firm Levi & Korsinsky, LLP launched an investigation into whether Regenxbio omitted material safety information prior to the FDA action. During the Q3 2025 earnings call on November 6, CEO Curran Simpson emphasized flawless FDA inspections of clinical sites and the in-house manufacturing facility but made no mention of emerging safety signals in the RGX-111 program. The absence of any discussion of that trial—later subject to the clinical hold—raises potential Rule 10b-5 issues under the Securities Exchange Act of 1934 regarding omissions of material facts.
4. Outlook and Investor Implications
With four clinical candidates advancing but two programs under hold, Regenxbio faces a critical path decision on additional safety studies and potential protocol amendments. Broker consensus rates the stock as a moderate Buy, with an average 12-month upside of 22% contingent on resumption of patient dosing by late 2026. Investors will closely monitor the timing of FDA feedback on the tumorgenicity findings and management’s next quarterly update for signs of revised trial timelines and budget guidance.